Cargando…
Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer
Context. Anaplastic thyroid cancer (ATC) is an aggressive tumor with a median survival of 3 to 9 months, a 1-year survival of less than 10% and without definitive therapies. Recently, in BRAF V600E mutated ATCs, new targeted therapy using a combination of a BRAF inhibitor, dabrafenib (Dab), with a m...
Autores principales: | Fazeli, Sasan, Paal, Edina, Maxwell, Jessica H., Burman, Kenneth D., Nylen, Eric S., Khosla, Shikha G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880026/ https://www.ncbi.nlm.nih.gov/pubmed/31766881 http://dx.doi.org/10.1177/2324709619890942 |
Ejemplares similares
-
Therapeutic advances in anaplastic thyroid cancer: a current perspective
por: Saini, Shikha, et al.
Publicado: (2018) -
Rhabdomyolysis in Patients Hospitalized With COVID-19 Infection: Five
Case Series
por: Khosla, Shikha G., et al.
Publicado: (2020) -
SUN-LB77 Incidental Anaplastic Thyroid Carcinoma: An Uncommon Entity
por: Padmanaban, Preethi, et al.
Publicado: (2020) -
A salutary exercise
por: CERN Bulletin
Publicado: (2010) -
Salutary Path for Progress
por: Patwardhan, Bhushan
Publicado: (2014)